B cells regulate immune responses by producing antigen-specific antibodies 1 . However, specific B-cell subsets can also negatively regulate T-cell immune responses, and have been termed regulatory B cells [2] [3] [4] . Human and mouse regulatory B cells (B10 cells) with the ability to express the inhibitory cytokine interleukin-10 (IL-10) have been identified [2] [3] [4] [5] . Although rare, B10 cells are potent negative regulators of antigen-specific inflammation and T-cell-dependent autoimmune diseases in mice [5] [6] [7] . How B10-cell IL-10 production and regulation of antigen-specific immune responses are controlled in vivo without inducing systemic immunosuppression is unknown. Using a mouse model for multiple sclerosis, here we show that B10cell maturation into functional IL-10-secreting effector cells that inhibit in vivo autoimmune disease requires IL-21 and CD40dependent cognate interactions with T cells. Moreover, the ex vivo provision of CD40 and IL-21 receptor signals can drive B10-cell development and expansion by four-million-fold, and generate B10 effector cells producing IL-10 that markedly inhibit disease symptoms when transferred into mice with established autoimmune disease. The ex vivo expansion and reinfusion of autologous B10 cells may provide a novel and effective in vivo treatment for severe autoimmune diseases that are resistant to current therapies.
A subset of regulatory B cells has been functionally defined in humans and mice by their ability to express IL-10 (refs 5 -7) . B cells that are competent to express IL-10 after 5 h of ex vivo phorbol ester and ionomycin stimulation are called B10 cells 6 to distinguish them from other regulatory B cells that modulate immune responses through other mechanisms 2, 8 . B10 cells are found at low frequencies (1-5%) in naive mice but expand with autoimmunity 9 . Spleen B10 cells are predominantly found within the minor CD1d hi CD5 1 B-cell subpopulation, along with B10 progenitor (B10pro) cells that are induced to become IL-10 competent during in vitro culture with agonistic CD40 monoclonal antibody or lipopolysaccharide (LPS) 9, 10 . The capacity of human and mouse B10 cells to produce IL-10 is central to their ability to negatively regulate inflammation and autoimmune disease, as well as innate and antigen-specific adaptive immune responses [5] [6] [7] [9] [10] [11] [12] , but the physiological signals controlling IL-10 production in vivo are unknown.
B10-cell immunoregulation is antigen specific, and B-cell antigen receptor (BCR) specificity markedly influences B10-cell development 6,9 . Receptors or pathways that positively or negatively regulate BCR signalling can also modulate B10-cell numbers in vivo. For example, CD19-deficient (Cd19 2/2 ) mice are essentially devoid of regulatory B10 cells, which leads to exacerbated inflammation and disease symptoms during contact hypersensitivity, and in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis 6, 7 . IL-10 itself is not required for B10-cell development as B cells with the capacity to express IL-10 reporter genes develop normally in Il10 2/2 mice 13 . B10cell numbers are also normal in T-cell-deficient nude mice and in mice deficient in expression of major histocompatibility complex class II (MHC-II) or CD40 molecules that are both important for cognate B-cell-T-cell interactions 9 . Consequently, appropriate BCR signals are thought to select a subset of B cells to become IL-10-competent B10 cells. Innate pathogen-induced signals also influence regulatory B10-cell IL-10 production in vivo 3, 13 . Little is otherwise known about how B10cell IL-10 production is regulated, and it remains unclear how these rare B cells exert such potent in vivo effects and selectively inhibit antigenspecific T-cell function during inflammation and autoimmunity.
To identify signals that regulate B10 cells in vivo, purified B cells were cultured with cytokines known to influence B-cell function. Stimulation with IL-21, but not IL-4, -6, -10, -12, -23 or -27, induced 2.7-to 3.2-fold higher B10-cell frequencies, and 4.4-to 5.3-fold more IL-10 secretion (P , 0.01) at 48 and 72 h, respectively, whereas interferon-c (IFN-c) or transforming growth factor-b (TGF-b) reduced IL-10 1 B-cell frequencies by 56% (P , 0.05; Fig. 1a ). In fact, IL-21 induced B10 cells to produce IL-10 without the need for in vitro stimulation ( Fig. 1b and Supplementary Fig. 1a ) and induced IL-10 secretion at levels similar to LPS stimulation ( Fig. 1a ). IL-21 also induced a threefold increase in IL-10 1 B cells within the spleen CD1d hi CD5 1 B-cell subset that is enriched for B10pro and B10 cells, but it did not induce IL-10 1 B cells among the CD1d lo CD5 2 subset ( Fig. 1b) . T-cellderived IL-21 has multiple important roles in B-cell effector function [14] [15] [16] [17] [18] , and IL-21 is a potent inducer of T-cell IL-10 production 19, 20 . Both B10 and non-B10 cells expressed cell surface IL-21 receptor (IL-21R) at similar levels ( Fig. 1c ). Despite this, ex vivo B10-, B10pro-and CD1d hi CD5 1 B-cell numbers were similar in wild-type, IL-21R-deficient (Il21r 2/2 ), MHC-II 2/2 and Cd40 2/2 mice (Supplementary Fig. 1b-d , data not shown). However, IL-21R expression was required for B10-cell expansion in vivo after myelin oligodendrocyte glycoprotein peptide (MOG ) immunizations to induce EAE ( Fig. 1d ). Thus, IL-21R-generated signals induced B10-cell expansion and IL-10 secretion in vivo.
Whether B10 cells require IL-21 to induce their regulatory function in vivo was determined by the adoptive transfer of Il21r 2/2 B cells into Cd19 2/2 mice before the induction of EAE. Because Cd19 2/2 mice are B10-cell deficient ( Fig. 1d ), their EAE disease severity is worse ( Fig. 2a) 7, 11 . The adoptive transfer of wild-type CD1d hi CD5 1 B cells normalized EAE severity in Cd19 2/2 mice. By contrast, the transfer of CD1d hi CD5 1 B cells from Il21r 2/2 or Il10 2/2 mice, or wild-type CD1d lo CD5 2 non-B10 cells, did not alter disease. Because CD4 1 T cells are a major source of IL-21, we determined whether cognate B10-T-cell interactions also controlled B10-cell-mediated suppression of EAE. The transfer of CD1d hi CD5 1 B cells from MHC-II 2/2 or Cd40 2/2 mice into Cd19 2/2 mice before MOG immunizations did not reduce EAE disease severity ( Fig. 2a , bottom right). CD1d lo CD5 2 B cells from Il21r 2/2 , Cd40 2/2 or MHC-II 2/2 mice were also without effect (data not shown). EAE is also exacerbated in wild-type mice depleted of mature B cells by CD20 monoclonal antibody 7, 11 . However, transfer of CD1d hi CD5 1 B cells from Cd20 2/2 mice, but not MHC-II 2/2 Cd20 2/2 mice, normalized disease severity in this model, and CD1d lo CD5 2 B cells from Cd20 2/2 or MHC-II 2/2 Cd20 2/2 mice were without effect ( Fig. 2b , data not shown). Similarly, the adoptive transfer of in vitro activated CD1d hi CD5 1 B cells from wild-type mice significantly reduced EAE disease severity in wild-type mice, whereas activated MHC-II 2/2 CD1d hi CD5 1 or wildtype CD1d lo CD5 2 B cells had no effect ( Fig. 2c , data not shown). Thus, regulatory B10-cell function required IL-10 expression and IL-21R signalling, as well as CD40 and MHC-II interactions, potentially explaining antigen-specific B10-cell effector function 6 . 
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Cd19 -/mice given PBS and MHC-II expression to regulate EAE severity. a, One day before Cd19 2/2 or wild-type (WT) mice were immunized with MOG 35 
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To determine whether cognate B10-T-cell interactions regulate antigen-specific T-cell proliferation in vivo, B10-cell function was assessed in MOG -immunized Cd19 2/2 mice after the adoptive transfer of dye-labelled CD4 1 T cells from transgenic mice expressing antigen receptors specific for the MOG (TCR MOG ) peptide 21 . CD1d hi CD5 1 B cells from naive wild-type mice significantly reduced TCR MOG CD4 1 T-cell proliferation, as measured by in vivo dye dilution (Fig. 3a) . CD1d hi CD5 1 B cells obtained from mice with EAE were even more potent inhibitors of T-cell proliferation, whereas CD1d lo CD5 2 B cells from wild-type mice, or CD1d hi CD5 1 B cells from Il10 2/2 , Il21r 2/2 , Cd40 2/2 , or MHC-II 2/2 mice were without effect. CD1d hi CD5 1 B cells from naive or antigen-experienced wildtype mice also significantly reduced TCR MOG CD4 1 T-cell IFN-c and IL-17 production in MOG 35-55 -immunized Cd19 2/2 mice, whereas CD1d hi CD5 1 B cells from Il10 2/2 , Il21r 2/2 , Cd40 2/2 or MHC-II 2/2 mice did not (Fig. 3b ). The ability of B10 cells to inhibit T-cell IL-17 production is particularly important because pathogenic T H , B10pro cells present peptides to antigen-specific T cells through cognate interactions that induce T-cell activation and CD40/CD154 interactions. Activated T cells may produce IL-21 locally, which binds to proximal B10 cell IL-21R (step 3). IL-21R signals induce B10-cell IL-10 production and effector function (B10eff, step 4) , which may negatively regulate antigen-specific T-cell function (step 5).
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T follicular helper cells isolated from mice with MOG 35-55 -induced EAE also express IL-21 (ref. 23) , and Cd19 2/2 mice have T follicular helper cells ( Supplementary Fig. 2) . Thus, B10 and T cells may require intimate interactions during reciprocal IL-10 and IL-21 production to optimally regulate antigen-specific disease (Fig. 3c ).
To verify that T-cell-derived IL-21 and CD40 signals drive B10-cell expansion and IL-10 production, B cells were cultured using optimized conditions that promote mouse B10-cell expansion in vivo 24 and B-cell expansion in vitro 25 . B cells were cultured on monolayers of NIH-3T3 cells expressing the T-cell ligand for CD40 (CD154) and B-lymphocyte stimulator (BLyS; also known as TNFSF13B) in the presence of IL-4, for 4 days to induce B10pro-cell maturation into IL-10-competent B10 cells. The B cells were then cultured on fresh NIH-3T3-CD154/BLyS cells with exogenous IL-21 for 5 days, which was essential to optimally expand B10 cells and induce IL-10 production (Fig. 4a ). After the 9-day culture period, B-cell and B10-cell numbers were increased by 25,000-and 4,000,000-fold, respectively, with 38% of the B cells actively producing IL-10 (Fig. 4b) . The vast majority of IL-10 1 B cells in the cultures expressed CD5 (Fig. 4c) , facilitating their purification and underscoring the marked effect of IL-21 on B10-cell numbers in vitro.
In vitro expanded CD5 1 B10 cells retained their regulatory function. The transfer of CD5 1 B10 cells markedly reduced EAE disease severity in wild-type mice, even when given after the appearance of disease symptoms, whereas CD5 2 B cells were without effect ( Fig. 4d ). Although the in vitro expansion of B10 cells required both IL-21R and CD40 signals, MHC-II expression was not required (Fig. 4e ). However, in vitro expanded MHC-II 2/2 CD5 1 B10 cells and Il10 2/2 CD5 1 B cells did not regulate EAE disease severity (Fig. 4f ), further showing a requirement for IL-10 and cognate interactions in the regulation of T-cell-mediated disease. B10 cells did not expand during in vitro cultures of B cells from Cd19 2/2 mice or MD4 transgenic mice 26 that have a fixed BCR specific for egg lysozyme (Fig. 4e ), highlighting the importance of BCR specificity and signalling in B10-cell generation. Otherwise, in vitro expanded B10 effector cells were potent regulators of both disease initiation and progression.
This study demonstrates that CD40 signals induce B10pro-cell acquisition of IL-10 competence, with IL-21 driving B10-cell expansion and effector cell generation. These critical checkpoints in B10-cell development may lead to localized IL-10 production that blunts antigen-specific T-cell responses during cognate interactions (Fig. 3c) , without untoward immunosuppression. Transient IL-10 production by B10 cells in vivo may further restrict the effects of IL-10 secretion 13 . B10 effector cells may also regulate T-cell responses to autoantigens in addition to MOG once inflammation and tissue destruction are initiated by MOG immunization. Because human and mouse B10 cells are also potent regulators of macrophage and dendritic cell function 5, 12 , T-cell induction of B10 effector cells may also contribute to EAE resolution by restraining monocyte and dendritic cell activation. Together, these results may explain in part why EAE is exacerbated in the absence of IL-21 signalling 27 . By contrast, TGF-b and IFN-c may counterbalance B10-cell expansion in vivo based on the current in vitro findings (Fig. 1a ). Regulatory T cells provide an independent layer of regulation during EAE, as their expansion, accumulation in the central nervous system, and suppressive activity are normal when B10 cells are absent 11, 28 . The in vitro recapitulation of these collective signals induced a severalmillion-fold expansion of B10 cells, and their functional maturation into potent B10 effector cells, which then reversed established autoimmune disease (Fig. 4) . In addition to BCR specificity, MHC-II expression remained an important checkpoint for B10 effector cell regulatory function during EAE (Fig. 4f) , as first described for regulatory type II monocytes 29 . Because autoimmunity has multigenic origins and autoantigens vary between patients and disease, in vitro expansion of the rare pool of human blood B10pro and B10 effector cells 5 may provide a potent future immunotherapy for individuals with severe autoimmune disease. Purified spleen B cells were cultured on NIH-3T3-CD154/BLyS-cell monolayers with exogenous IL-4 for 4 days, then cultured on fresh NIH-3T3-CD154/BLyS cells with exogenous IL-21 for 3 or 5 days as indicated, isolated, cultured with monensin for 5 h and stained for cytoplasmic IL-10 expression. Representative IL-10 1 B-cell frequencies within the indicated gates are shown. Similar results were obtained in $10 experiments. b, IL-21 drives B10-cell expansion in vitro. B cells cultured as in a were harvested each day. Bar values represent mean (6 s.e.m.) B-cell and B10-cell numbers, or B10cell frequencies (solid line) from three independent experiments. c, IL-21induced B10 cells express CD5. B cells cultured for 9 days as in a were stained for CD5 and CD19 expression. CD5 1 or CD5 2 B cells were then purified and cultured with monensin for 5 h before cytoplasmic IL-10 staining. Results represent three independent experiments. d, B10 effector cells inhibit EAE initiation and progression. CD5 1 CD19 1 or CD5 2 CD19 1 cells were isolated as in c and adoptively transferred into wild-type mice on days 21, 7, 14 or 21 (arrows) before/after MOG immunization and EAE induction, as in Fig. 2 . e, B10-cell expansion in vitro requires IL-21R and CD40 expression, and in vivo BCR signalling. Purified spleen B cells isolated from wild-type, Il21r 2/2 , Cd40 2/2 , MHC-II 2/2 , Cd19 2/2 or MD4 mice were cultured as in a, with mean (6 s.e.m.) cell numbers quantified after culture. Values represent means 6 s.e.m. of three independent experiments. IL-10 1 B-cell frequencies in the cultures are shown in parentheses. f, B10 effector cells require IL-10 and MHC-II expression to inhibit EAE. B cells from Il10 2/2 or MHC-II 2/2 mice were cultured as in a, separated into CD5 1 or CD5 2 cells as in c, and adoptively transferred into wild-type mice before MOG immunization as in d. d, f, Values represent mean (6 s.e.m.) symptom scores from $3 mice in each group, with similar results obtained in three independent experiments. b, d, e, Significant differences between sample means are indicated: *P , 0.05; **P , 0.01.
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METHODS SUMMARY
Mice. Mice were used at 6-12 weeks of age. The Duke University and National Heart, Lung, and Blood Institute Animal Care and Use Committee approved all studies. Immunofluorescence analysis. For two-to six-colour immunofluorescence analysis, single-cell spleen suspensions were purified, stained and analysed as described 6,7,11,30 . In vitro B-cell cultures. Purified splenic B cells (95-98%) were cultured with either recombinant IFN-c (10 ng ml 21 ), IL-4 (2 ng ml 21 ), IL-6 (10 ng ml 21 ), IL-21 (100 ng ml 21 ), TGF-b (10 ng ml 21 ), IL-10 (10 ng ml 21 ), IL-12 (10 ng ml 21 ), IL-23 (20 ng ml 21 ), IL-27 (100 ng ml 21 ), LPS (10 mg ml 21 ), or CD40 monoclonal antibody (1 mg ml 21 ) before B10-cell numbers were determined. In separate experiments, purified spleen B cells were cultured with NIH-3T3 cells expressing CD154 and BLyS, with exogenous recombinant IL-4 (2 ng ml 21 ) or IL-21 (10 ng ml 21 ) 25 . IL-10 concentrations were determined by ELISA. EAE and adoptive transfer experiments. Purified B-cell and TCR MOG T-cell subsets (95-98% pure) were transferred into recipient mice as described 6, 7, 11, 30 . Of the CD1d hi CD5 1 or CD1d lo CD5 2 B cells (1 3 10 6 ) transferred, 13-20% and ,0.1% were B10 cells, respectively 6, 30 . Active EAE was induced and scored as described 7, 11 . Statistical analysis. All data are shown as means 6 s.e.m. Significant differences between sample means were determined using the Student's t-test.
